Bactiguard Holding AB has announced an update to its trauma license partnership agreement with Zimmer Biomet. The revised agreement focuses on the continued commercialization of the ZNN Bactiguard coated trauma nail system in European markets, selected Middle East and Africa (MEA) markets, and Japan. Under the new terms, Bactiguard will receive royalties on actual net sales and a quarterly fixed fee from Zimmer Biomet, with the annual fixed fees amounting to at least half of the minimum royalty from the previous agreement. The updated agreement is effective immediately and will not negatively impact Bactiguard's financial outlook for 2025 or its strategic and financial targets for 2030. Bactiguard also regains the remaining global rights within trauma as part of the update.